CD69 and glioblastoma: Compared to healthy individuals (n = 15) the proportion of activated NK cells (CD3+/CD69+) in glioblastoma patients who remained progression-free for 6 months (**p < 0.01) was significantly higher (Supplementary Figure S3B).